VYNE Therapeutics Inc.
VYNENasdaq
$0.76
↓ -0.8%Jul 17 close · end-of-day
Price
1Y↓ -39.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$32.5M
Enterprise Value
$7.6M
P/E
—
P/S
57.1
P/B
1.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$570,000.00
Net Income (TTM)
-$26.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-5219.1%
Net Margin
—
ROE
—
ROIC
—
Debt / Equity
0.0
Net Cash
$24.9M
Return 1Y
-36.6%
Company profile
VYNE Therapeutics Inc. focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the. treatment of moderate-to-severe acne vulgaris. FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial. for mild to moderate atopic dermatitis, is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor.
- CEO
- David Domzalski
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- New Jersey
- Website
- vynetherapeutics.com
Management & directors
- Domzalski DavidPRESIDENT AND CEO
- Harsch MutyaCHIEF LEGAL OFFICER AND GC
- Stuart IainCHIEF SCIENTIFIC OFFICER
- Zeronda TylerCHIEF FINANCIAL OFFICER
Roles derived from SEC Form 4 filings.
Earnings
VYNE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$86,000.00↓ -57.4%
Diluted EPS-$0.08↓ -60.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $21.0M | $931,000.00 | $477,000.00 | $424,000.00 | $501,000.00 | $570,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$252.5M | -$38.9M | -$34.3M | -$29.3M | -$43.6M | -$29.7M |
| Net income | -$255.6M | -$73.3M | -$23.2M | -$28.5M | -$39.8M | -$26.5M |
| Diluted EPS | $7.88 | -$25.64 | -$7.28 | -$2.78 | -$0.93 | -$0.62 |
| Operating cash flow | -$137.1M | -$56.4M | -$29.2M | -$25.3M | -$34.0M | -$33.1M |
| Free cash flow | -$137.2M | -$56.4M | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -1203.0% | -4179.5% | -7189.7% | -6900.5% | -8710.0% | -5219.1% |
| Net margin | -1217.4% | -7876.4% | -4865.8% | -6710.4% | -7950.9% | -4646.1% |
| Line item | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $76,000.00 | $98,000.00 | $198,000.00 | $121,000.00 | $84,000.00 | $202,000.00 | $69,000.00 | $86,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$6.8M | -$7.4M | -$10.4M | -$13.1M | -$12.8M | -$9.2M | -$7.5M | -$3.8M |
| Net income | -$6.2M | -$6.2M | -$9.4M | -$12.2M | -$12.0M | -$8.6M | -$5.8M | -$3.6M |
| Diluted EPS | $4.06 | -$0.15 | -$0.22 | -$0.29 | -$0.27 | -$0.20 | -$0.13 | -$0.08 |
| Operating cash flow | -$5.1M | -$8.0M | -$8.5M | -$8.5M | -$9.0M | -$11.5M | -$10.8M | -$4.1M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -8988.2% | -7530.6% | -5250.5% | -10819.0% | -15202.4% | -4553.0% | -10930.4% | -4437.2% |
| Net margin | -8142.1% | -6376.5% | -4750.5% | -10047.1% | -14311.9% | -4262.9% | -8340.6% | -4168.6% |
Company news
Dec 17, 2025
Nov 6, 2025
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Domzalski David· PRESIDENT AND CEO | Tax withholding | 12,214 | $0.65 | $7,947.65 | filing |
| 2026-06-30 | Harsch Mutya· CHIEF LEGAL OFFICER AND GC | Tax withholding | 3,464 | $0.65 | $2,254.02 | filing |
| 2026-06-30 | Zeronda Tyler· CHIEF FINANCIAL OFFICER | Tax withholding | 3,464 | $0.65 | $2,254.02 | filing |
| 2026-06-30 | Stuart Iain· CHIEF SCIENTIFIC OFFICER | Tax withholding | 2,370 | $0.65 | $1,542.16 | filing |
| 2026-05-29 | Domzalski David· PRESIDENT AND CEO | Award | 30,791 | $0.31 | $9,545.21 | filing |
| 2026-03-31 | Domzalski David· PRESIDENT AND CEO | Tax withholding | 14,232 | $0.60 | $8,503.62 | filing |
| 2026-03-31 | Zeronda Tyler· CHIEF FINANCIAL OFFICER | Tax withholding | 4,007 | $0.60 | $2,394.18 | filing |
| 2026-03-31 | Harsch Mutya· CHIEF LEGAL OFFICER AND GC | Tax withholding | 4,007 | $0.60 | $2,394.18 | filing |
| 2026-03-31 | Stuart Iain· CHIEF SCIENTIFIC OFFICER | Tax withholding | 2,876 | $0.60 | $1,718.41 | filing |
| 2025-12-31 | Domzalski David· PRESIDENT AND CEO | Tax withholding | 12,684 | $0.58 | $7,357.99 | filing |
| 2025-12-31 | Zeronda Tyler· CHIEF FINANCIAL OFFICER | Tax withholding | 7,858 | $0.58 | $4,558.43 | filing |
| 2025-12-31 | Harsch Mutya· CHIEF LEGAL OFFICER AND GC | Tax withholding | 3,579 | $0.58 | $2,076.18 | filing |
| 2025-12-31 | Stuart Iain· CHIEF SCIENTIFIC OFFICER | Tax withholding | 2,448 | $0.58 | $1,420.08 | filing |
| 2025-09-30 | Domzalski David· PRESIDENT AND CEO | Tax withholding | 12,676 | $0.34 | $4,246.46 | filing |
| 2025-09-30 | Harsch Mutya· CHIEF LEGAL OFFICER AND GC | Tax withholding | 3,581 | $0.34 | $1,199.64 | filing |
| 2025-09-30 | Zeronda Tyler· CHIEF FINANCIAL OFFICER | Tax withholding | 3,420 | $0.34 | $1,145.70 | filing |
| 2025-09-30 | Stuart Iain· CHIEF SCIENTIFIC OFFICER | Tax withholding | 2,453 | $0.34 | $821.76 | filing |
| 2025-06-30 | Domzalski David· PRESIDENT AND CEO | Tax withholding | 12,676 | $1.65 | $20,915.40 | filing |
| 2025-06-30 | Harsch Mutya· CHIEF LEGAL OFFICER AND GC | Tax withholding | 3,581 | $1.65 | $5,908.65 | filing |
| 2025-06-30 | Zeronda Tyler· CHIEF FINANCIAL OFFICER | Tax withholding | 3,420 | $1.65 | $5,643.00 | filing |
| 2025-06-30 | Stuart Iain· CHIEF SCIENTIFIC OFFICER | Tax withholding | 2,453 | $1.65 | $4,047.45 | filing |
Latest 21 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.